Cyncado Therapeutics
- Biotech or pharma, therapeutic R&D
Clinical-stage immuno-oncology pioneer delivering the first complete blockade of the adenosine pathway in cancer. Two potent, highly selective oral A2A and A2B antagonists are co-administered to re-ignite T/NK cells, curb Treg/MDSC suppression and shut down VEGF-driven angiogenesis, rapidly turning cold tumors hot. Seeking partners to accelerate clinical development.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}